|
KMID : 1040620240300010016
|
|
Clinical and Molecular Hepatology
2024 Volume.30 No. 1 p.16 ~ p.36
|
|
|
Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases
|
|
Pin-Nan Cheng
Wen-Jone Chen
Charles Jia-Yin Hou
Chih-Lin Lin
Ming-Ling Chang
Chia-Chi Wang
Wei-Ting Chang
Chao-Yung Wang
Chun-Yen Lin
Chung-Lieh Hung
Cheng-Yuan Peng
Ming-Lung Yu
Ting-Hsing Chao
Jee-Fu Huang
Yi-Hsiang Huang
Chi-Yi Chen
Chern-En Chiang
Han-Chieh Lin
Yi-Heng Li
Tsung-Hsien Lin
Jia-Horng Kao
Tzung-Dau Wang
Ping-Yen Liu
Yen-Wen Wu
Chun-Jen Liu
|
|
|
Abstract
|
|
|
|
Metabolic dysfunction-associated fatty liver disease (MAFLD) is an increasingly common liver disease worldwide. MAFLD is diagnosed based on the presence of steatosis on images, histological findings, or serum marker levels as well as the presence of at least one of the three metabolic features: overweight/obesity, type 2 diabetes mellitus, and metabolic risk factors. MAFLD is not only a liver disease but also a factor contributing to or related to cardiovascular diseases (CVD), which is the major etiology responsible for morbidity and mortality in patients with MAFLD. Hence, understanding the association between MAFLD and CVD, surveillance and risk stratification of MAFLD in patients with CVD, and assessment of the current status of MAFLD management are urgent requirements for both hepatologists and cardiologists. This Taiwan position statement reviews the literature and provides suggestions regarding the epidemiology, etiology, risk factors, risk stratification, nonpharmacological interventions, and potential drug treatments of MAFLD, focusing on its association with CVD.
|
|
|
KEYWORD
|
|
|
MAFLD, Cardiovascular disease, Position statement, Taiwan
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|